149 related articles for article (PubMed ID: 19439722)
1. Seeing injectable MS therapies differently: they are more similar than different.
Fox RJ; Arnold DL
Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
[No Abstract] [Full Text] [Related]
2. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
3. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Giacomini PS; Arnold DL; Bar-Or A; Antel JP
Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
[No Abstract] [Full Text] [Related]
4. Seeing injectable ms therapies differently: they are more similar than different.
Johnson KP; Fox RJ; Arnold DL
Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
[No Abstract] [Full Text] [Related]
5. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity measurement of CRP and disease progression in multiple sclerosis.
Soilu-Hänninen M; Koskinen JO; Laaksonen M; Hänninen A; Lilius EM; Waris M
Neurology; 2005 Jul; 65(1):153-5. PubMed ID: 16009907
[TBL] [Abstract][Full Text] [Related]
7. The use of MRI as an outcome measure in clinical trials.
Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
[TBL] [Abstract][Full Text] [Related]
8. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
9. Early treatment of multiple sclerosis to prevent neurologic damage.
Coyle PK
Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
Cristiano E
Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
[TBL] [Abstract][Full Text] [Related]
11. What can be learned from open direct comparative trials in multiple sclerosis?
Khan O
J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
[TBL] [Abstract][Full Text] [Related]
13. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
14. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
15. CSF analysis in suspected MS: do bands aid?
Hintzen RQ; Giovannoni G
Neurology; 2008 Mar; 70(13 Pt 2):1059-60. PubMed ID: 18362264
[No Abstract] [Full Text] [Related]
16. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
18. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
19. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
Barkhof F; van Waesberghe JH; Uitdehaag BM; Polman CH
Ann Neurol; 1997 Dec; 42(6):982. PubMed ID: 9403493
[No Abstract] [Full Text] [Related]
20. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
Freedman MS; Forrestal FG
Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]